Advertisement

Archives of Orthopaedic and Trauma Surgery

, Volume 139, Issue 5, pp 623–627 | Cite as

The effects of radiosynoviorthesis in pigmented villonodular synovitis of the knee

  • Hans Roland DürrEmail author
  • Carl Ferdinand Capellen
  • Alexander Klein
  • Andrea Baur-Melnyk
  • Christof Birkenmaier
  • Volkmar Jansson
  • Reinhold Tiling
Orthopaedic Surgery
  • 62 Downloads

Abstract

Introduction

Tenosynovial giant-cell tumor also known as pigmented villonodular synovitis (PVS) is a benign but aggressive synovial proliferative disease most often affecting the knee joint. The mainstay of therapy is surgical resection. Due to a high rate of local recurrence, radiosynoviorthesis (RSO) is used as an adjuvant method in many cases. The aim of this study was to compare local recurrence (LR) rates after surgical synovectomy with and without adjuvant RSO.

Materials and methods

From 1996 to 2014, 37 surgical interventions were performed in 32 patients with diffuse pigmented villonodular synovitis of the knee. All patients underwent open synovectomy. Adjuvant radiosynoviorthesis (RSO) was applied in 26 cases, the control group consists of 11 cases without RSO.

Results

9 (24%) lesions recurred within a median of 19 months after surgery. Of those 9 recurrences, 3 (17%) were seen in primary disease, 6 (32%) in already recurring cases (n.s.). In 26 RSO treated patients 6 (23%) recurred, in 11 patients of the control group, 3 (27%) recurred (n.s.).

Conclusions

RSO is effective in PVS as also shown in some smaller reports in the literature. But surgery is still the mainstay of therapy. RSO is not a method of compensating for an insufficient surgical approach, but it may reduce the high rate of LR in patients with large and even recurrent diffuse forms of the disease.

Keywords

Synovitis Pigmented villonodular Giant cell tumor of tendon sheath Synovectomy Neoplasm recurrence Local Radiosynoviorthesis 

Notes

Funding

All authors have no financial and personal relationships with other people or organizations that could inappropriately influence (bias) this work. This study was not supported by any grants or external funding.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

This study was approved by the ethics committee of the Medical Faculty, University of Munich.

Informed consent

Written consent was obtained from all patients included in this study.

Data availability

The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

References

  1. 1.
    Auregan JC, Klouche S, Bohu Y, Lefevre N, Herman S, Hardy P (2014) Treatment of pigmented villonodular synovitis of the knee. Arthroscopy 30(10):1327–1341CrossRefGoogle Scholar
  2. 2.
    Bruns J, Ewerbeck V, Dominkus M et al (2013) Pigmented villo-nodular synovitis and giant-cell tumor of tendon sheaths: a binational retrospective study. Arch Orthop Trauma Surg 133(8):1047–1053CrossRefGoogle Scholar
  3. 3.
    Capellen CF, Tiling R, Klein A, Baur-Melnyk A, Knösel T, Birkenmaier C, Roeder F, Jansson V, Dürr HR (2018) Lowering the recurrence rate in pigmented villonodular synovitis: a series of 120 resections. Rheumatology (Oxford) 57(8):1448–1452Google Scholar
  4. 4.
    Chassaignac M (1852) Cancer de la gaine des tendons. Gaz Hop Civ Milit 25:185–186Google Scholar
  5. 5.
    Chin KR, Barr SJ, Winalski C, Zurakowski D, Brick GW (2002) Treatment of advanced primary and recurrent diffuse pigmented villonodular synovitis of the knee. J Bone Joint Surg Am 84-A(12):2192–2202CrossRefGoogle Scholar
  6. 6.
    Dürr HR, Stäbler A, Maier M, Refior HJ (2001) Pigmented villonodular synovitis. Review of 20 cases. J Rheumatol 28(7):1620–1630Google Scholar
  7. 7.
    Franssen MJ, Boerbooms AM, Karthaus RP, Buijs WC, van de Putte LB (1989) Treatment of pigmented villonodular synovitis of the knee with yttrium-90 silicate: prospective evaluations by arthroscopy, histology, and 99mTc pertechnetate uptake measurements. Ann Rheum Dis 48(12):1007–1013CrossRefGoogle Scholar
  8. 8.
    Gumpel JM, Shawe DJ (1991) Diffuse pigmented villonodular synovitis: non-surgical management. Ann Rheum Dis 50(8):531–533CrossRefGoogle Scholar
  9. 9.
    Hufeland M, Gesslein M, Perka C, Schroder JH (2018) Long-term outcome of pigmented villonodular synovitis of the hip after joint preserving therapy. Arch Orthop Trauma Surg 138(4):471–477CrossRefGoogle Scholar
  10. 10.
    Jaffe HL, Lichtenstein L, SuroC.J (1941) Pigmented villonodular synovitis, bursitis and tenosynovitis. Arch Pathol 31:731–765Google Scholar
  11. 11.
    Kat S, Kutz R, Elbracht T, Weseloh G, Kuwert T (2000) Radiosynovectomy in pigmented villonodular synovitis. Nuklearmedizin 39(7):209–213CrossRefGoogle Scholar
  12. 12.
    Koca G, Ozsoy H, Atilgan HI et al (2013) A low recurrence rate is possible with a combination of surgery and radiosynovectomy for diffuse pigmented villonodular synovitis of the knee. Clin Nucl Med 38(8):608–615CrossRefGoogle Scholar
  13. 13.
    Li W, Sun X, Lin J, Ji W, Ruan D (2015) Arthroscopic synovectomy and postoperative assisted radiotherapy for treating diffuse pigmented villonodular synovitis of the knee: an observational retrospective study. Pak J Med Sci 31(4):956–960Google Scholar
  14. 14.
    Mirra JM, Picci P, Gold RH (1989) Pigmented villonodular synovitis invading bone. In: Bone tumors, clinical, radiologic and pathologic correlations. Lea and Febiger, Philadelphia, pp 1766–1775Google Scholar
  15. 15.
    Mollon B, Lee A, Busse JW et al (2015) The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis. Bone Joint J 97-B(4):550–557CrossRefGoogle Scholar
  16. 16.
    Myers BW, Masi AT (1980) Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiologic study of 166 cases and literature review. Medicine (Baltimore) 59(3):223–238CrossRefGoogle Scholar
  17. 17.
    Ottaviani S, Ayral X, Dougados M, Gossec L (2011) Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arthritis Rheum 40(6):539–546CrossRefGoogle Scholar
  18. 18.
    Ozturk H, Bulut O, Oztemur Z, Bulut S (2008) Pigmented villonodular synovitis managed by Yttrium 90 after debulking surgery. Saudi Med J 29(8):1197–1200Google Scholar
  19. 19.
    Park G, Kim YS, Kim JH et al (2012) Low-dose external beam radiotherapy as a postoperative treatment for patients with diffuse pigmented villonodular synovitis of the knee: 4 recurrences in 23 patients followed for mean 9 years. Acta Orthop 83(3):256–260CrossRefGoogle Scholar
  20. 20.
    Shabat S, Kollender Y, Merimsky O et al (2002) The use of surgery and yttrium 90 in the management of extensive and diffuse pigmented villonodular synovitis of large joints. Rheumatology 41(10):1113–1118CrossRefGoogle Scholar
  21. 21.
    Tap WD, Wainberg ZA, Anthony SP et al (2015) Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med 373(5):428–437CrossRefGoogle Scholar
  22. 22.
    Ward Sr. WG, Boles CA, Ball JD, Cline MT (2007) Diffuse pigmented villonodular synovitis: preliminary results with intralesional resection and p32 synoviorthesis. Clin Orthop Relat Res 454:186–191CrossRefGoogle Scholar
  23. 23.
    West RB, Rubin BP, Miller MA et al (2006) A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 103(3):690–695CrossRefGoogle Scholar
  24. 24.
    Xie GP, Jiang N, Liang CX et al (2015) Pigmented villonodular synovitis: a retrospective multicenter study of 237 cases. PLoS One 10(3):e0121451CrossRefGoogle Scholar
  25. 25.
    Zook JE, Wurtz DL, Cummings JE, Cardenes HR (2011) Intra-articular chromic phosphate ((3)(2)P) in the treatment of diffuse pigmented villonodular synovitis. Brachytherapy 10(3):190–194CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Hans Roland Dürr
    • 1
    Email author
  • Carl Ferdinand Capellen
    • 1
  • Alexander Klein
    • 1
  • Andrea Baur-Melnyk
    • 3
  • Christof Birkenmaier
    • 1
  • Volkmar Jansson
    • 1
  • Reinhold Tiling
    • 2
  1. 1.Musculoskeletal Oncology, Department of Orthopaedics, Physical Medicine and RehabilitationUniversity Hospital, LMU MunichMunichGermany
  2. 2.Department of Nuclear MedicineUniversity Hospital, LMU MunichMunichGermany
  3. 3.Institute of RadiologyUniversity Hospital, LMU MunichMunichGermany

Personalised recommendations